bavisant
Small moleculeexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00566449)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1- Mol. weight
- 329.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103862 ↗
Also known as
- 31001074
- bavisant
- bavisant
- bavisant
- bavisant
- bavisant
- jnj-31001074
- jnj-31001074
- jnj-31001074
- jnj-31001074
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03194217 | Phase 2 | Sep 1, 2017 | BenevolentAI Bio, Methodist Cancer Center, Houston, Texas |
| NCT01362699 | Phase 2 | Aug 1, 2011 | Johnson and Johnson, Scripps |
| NCT01159821 | Phase 1 | Aug 1, 2010 | Johnson and Johnson |
| NCT00915746 | Phase 1 | Nov 1, 2009 | Johnson and Johnson |
| NCT00915668 | Phase 1 | Jun 4, 2009 | Johnson and Johnson |
| NCT00915434 | Phase 1 | Jun 1, 2009 | Johnson and Johnson |
| NCT00890292 | Phase 1 | May 1, 2009 | Johnson and Johnson |
| NCT00890240 | Phase 1 | May 1, 2009 | Johnson and Johnson |
| NCT00880217 | Phase 2 | May 1, 2009 | Johnson and Johnson |
| NCT00566449 | Phase 2 | Dec 1, 2007 | Alza, Johnson and Johnson |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 9 | 9 | 2 | 2007 |
| Alza | For profit | 1 | 0 | 1 | 2007 |
| BenevolentAI Bio | For profit | 1 | 1 | 1 | 2017 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Scripps | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1